Janux Therapeutics posts 2022 net loss of $63.1M; cash at $327M; JANX007 update expected 2H 2023

Janux Therapeutics, Inc.

Net loss of $63.1M for FY2022, vs $32.7M in FY2021; R&D expenses doubled to $53.4M.
Cash and short-term investments $327.0M at Dec 31, 2022, down from $375.0M at Dec 31, 2021.
FDA clearance for JANX008 (EGFR-TRACTr) IND; JANX009 IND submission on track 2023.
Interim clinical update from JANX007 (PSMA-TRACTr) Phase 1 trial expected in H2 2023.
Janux states SVB exposure is immaterial and will not impact short- or long-term objectives.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Janux Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss was $16.1 million for the quarter and $63.1 million for the year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Net income: Net loss was $16.1 million for the quarter and $63.1 million for the year ended December 31, 2022
Result: reported results

Exact text from the filing

Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-007286

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.